BRIEF published on 07/22/2026 at 08:35, 19 days 2 hours ago Rubean AG étend la portée de SofTPOS à 150 000 terminaux Rubean AG Prévisions De Revenus Expansion FinTech Application SofTPOS Paiements Sans Espèces
BRIEF published on 07/22/2026 at 08:35, 19 days 2 hours ago Rubean AG Expands SofTPOS Reach to 150,000 Terminals Revenue Forecast Rubean AG Fintech Expansion SoftPOS App Cashless Payments
PRESS RELEASE published on 07/22/2026 at 08:30, 19 days 2 hours ago Rubean AG: SofTPOS App now available on over 150,000 active terminals Rubean AG's SofTPOS app now on 150,000+ terminals. User numbers doubled YoY, recurring revenue set to double in 2026. Market leader in cashless payments Revenue Forecast Rubean AG Market Leader SoftPOS App Cashless Payments
BRIEF published on 07/08/2026 at 13:05, 1 month 1 day ago Rubean AG prévoit une croissance continue de sa rentabilité Revenus Récurrents Rubean AG Croissance Des Revenus Expansion Du Marché Logiciel SoftPOS
BRIEF published on 07/08/2026 at 13:05, 1 month 1 day ago Rubean AG Projects Continued Profitability Growth Revenue Growth Recurring Revenue Rubean AG Market Expansion SoftPOS Software
PRESS RELEASE published on 07/08/2026 at 13:00, 1 month 1 day ago Rubean AG Is Growing Increasingly Profitably Rubean AG expects substantial revenue growth in 2026 and 2027, with a focus on recurring revenue and positive earnings. The FinTech company offers software-only point-of-sale solutions Revenue Growth Recurring Revenue Fintech Rubean AG Positive Earnings
BRIEF published on 07/01/2026 at 08:35, 1 month 9 days ago New Leadership at Rubean AG Aims for Growth Rubean AG Market Expansion Leadership Change Fintech Growth SoftPOS Technology
BRIEF published on 07/01/2026 at 08:35, 1 month 9 days ago La nouvelle direction de Rubean AG vise la croissance Rubean AG Changement De Leadership Expansion Du Marché Croissance De La Fintech Technologie SoftPOS
PRESS RELEASE published on 07/01/2026 at 08:30, 1 month 9 days ago New Leadership Team at Rubean Takes Office New Leadership Team at Rubean AG takes office with Stephan Kück joining Jochen Pielage as Co-CEO, focusing on sales expansion for significant growth opportunities Leadership Team Rubean AG Sales Expansion Jochen Pielage Stephan Kück
BRIEF published on 05/21/2026 at 12:16, 2 months 19 days ago Stephan Kueck Joins Rubean AG as Co-CEO Growth Strategy Fintech Rubean AG Leadership Appointment Stephan Kueck
Published on 08/10/2026 at 08:00, 2 hours 48 minutes ago Galantas Gold Expands Indiana Drill Program to 12,500 Metres
Published on 08/10/2026 at 08:00, 2 hours 48 minutes ago Results of AGM and Management Update Presentation
Published on 08/07/2026 at 23:15, 2 days 11 hours ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days 11 hours ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/10/2026 at 10:12, 35 minutes ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 08/10/2026 at 10:10, 37 minutes ago Hana Bank Subsidiary GLN Expands QR Payment Network for International Travelers to Korea
Published on 08/10/2026 at 09:50, 58 minutes ago Photon Energy N.V. Bond 21/27 (ISIN: DE000A3KWKY4): Signs of a crisis are mounting. What can investors do? Invitation to video conferences (German/English)
Published on 08/10/2026 at 09:00, 1 hour 47 minutes ago Original-Research: Rosenbauer International AG (von NuWays AG): BUY
Published on 08/10/2026 at 09:00, 1 hour 47 minutes ago Original-Research: Bittium Oyj (von NuWays AG): BUY
Published on 08/10/2026 at 09:22, 1 hour 25 minutes ago Number of shares and voting rights - July 2026 (In French only)
Published on 08/10/2026 at 09:22, 1 hour 25 minutes ago Nombre total d'actions et droits de vote - juillet 2026
Published on 08/10/2026 at 07:00, 3 hours 48 minutes ago BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Published on 08/10/2026 at 07:00, 3 hours 48 minutes ago Biophytis annonce l’autorisation de l’étude clinique OBA au Brésil et partage les perspectives de BIO101 dans l’obésité
